76 related articles for article (PubMed ID: 2843483)
1. Monoclonal antibodies provide protection against ocular Pseudomonas aeruginosa infection.
Moon MM; Hazlett LD; Hancock RE; Berk RS; Barrett R
Invest Ophthalmol Vis Sci; 1988 Aug; 29(8):1277-84. PubMed ID: 2843483
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
[TBL] [Abstract][Full Text] [Related]
3. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
[TBL] [Abstract][Full Text] [Related]
4. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
von Specht BU; Domdey H; Schödel F; Blum B; Lücking C; Knapp B; Muth G; Hungerer KD; Bröker M
Behring Inst Mitt; 1994 Dec; (95):85-96. PubMed ID: 7538752
[TBL] [Abstract][Full Text] [Related]
5. Secretory IgA inhibits Pseudomonas aeruginosa binding to cornea and protects against keratitis.
Masinick SA; Montgomery CP; Montgomery PC; Hazlett LD
Invest Ophthalmol Vis Sci; 1997 Apr; 38(5):910-8. PubMed ID: 9112987
[TBL] [Abstract][Full Text] [Related]
6. Perlecan in the basement membrane of corneal epithelium serves as a site for P. aeruginosa binding.
Chen LD; Hazlett LD
Curr Eye Res; 2000 Apr; 20(4):260-7. PubMed ID: 10806439
[TBL] [Abstract][Full Text] [Related]
7. Immunization against experimental Pseudomonas aeruginosa and Serratia marcescens keratitis. Vaccination with lipopolysaccharide endotoxins and proteases.
Kreger AS; Lyerly DM; Hazlett LD; Berk RS
Invest Ophthalmol Vis Sci; 1986 Jun; 27(6):932-9. PubMed ID: 3519522
[TBL] [Abstract][Full Text] [Related]
8. Immunoprotection by monoclonal antibodies to the porins and lipopolysaccharide of Salmonella typhimurium.
Singh SP; Williams YU; Benjamin WH; Klebba PE; Boyd D
Microb Pathog; 1996 Oct; 21(4):249-63. PubMed ID: 8905614
[TBL] [Abstract][Full Text] [Related]
9. Evidence for TIMP-1 protection against P. aeruginosa-induced corneal ulceration and perforation.
Kernacki KA; Barrett R; Hazlett LD
Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3168-76. PubMed ID: 10586939
[TBL] [Abstract][Full Text] [Related]
10. Immunization with homologous Pseudomonas aeruginosa pili protects against ocular disease.
Rudner XL; Berk RS; Hazlett LD
Reg Immunol; 1993; 5(5):245-52. PubMed ID: 7908533
[TBL] [Abstract][Full Text] [Related]
11. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
[TBL] [Abstract][Full Text] [Related]
12. Oral vaccination and multivalent vaccine against Pseudomonas aeruginosa keratitis.
Gerke JR; Nelson JS
Invest Ophthalmol Vis Sci; 1977 Jan; 16(1):76-80. PubMed ID: 832968
[TBL] [Abstract][Full Text] [Related]
13. Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies.
Finke M; Muth G; Reichhelm T; Thoma M; Duchêne M; Hungerer KD; Domdey H; von Specht BU
Infect Immun; 1991 Apr; 59(4):1251-4. PubMed ID: 1706316
[TBL] [Abstract][Full Text] [Related]
14. Association of CD4+ T cell-dependent keratitis with genetic susceptibility to Pseudomonas aeruginosa ocular infection.
Kwon B; Hazlett LD
J Immunol; 1997 Dec; 159(12):6283-90. PubMed ID: 9550433
[TBL] [Abstract][Full Text] [Related]
15. Role of complement in murine corneal infection caused by Pseudomonas aeruginosa.
Cleveland RP; Hazlett LD; Leon MA; Berk RS
Invest Ophthalmol Vis Sci; 1983 Feb; 24(2):237-42. PubMed ID: 6826327
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of type-specific and cross-reactive murine monoclonal antibodies directed against endotoxin during experimental sepsis.
Dunn DL; Bogard WC; Cerra FB
Surgery; 1985 Aug; 98(2):283-90. PubMed ID: 3895540
[TBL] [Abstract][Full Text] [Related]
17. Nona-D-arginine therapy for Pseudomonas aeruginosa keratitis.
Karicherla P; Hobden JA
Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):256-62. PubMed ID: 18775859
[TBL] [Abstract][Full Text] [Related]
18. Role of IL-12 and IFN-gamma in Pseudomonas aeruginosa corneal infection.
Hazlett LD; Rudner XL; McClellan SA; Barrett RP; Lighvani S
Invest Ophthalmol Vis Sci; 2002 Feb; 43(2):419-24. PubMed ID: 11818386
[TBL] [Abstract][Full Text] [Related]
19. Increased severity of Pseudomonas aeruginosa corneal infection in strains of mice designated as Th1 versus Th2 responsive.
Hazlett LD; McClellan S; Kwon B; Barrett R
Invest Ophthalmol Vis Sci; 2000 Mar; 41(3):805-10. PubMed ID: 10711697
[TBL] [Abstract][Full Text] [Related]
20. Chimeric influenza viruses incorporating epitopes of outer membrane protein F as a vaccine against pulmonary infection with Pseudomonas aeruginosa.
Gilleland HE; Gilleland LB; Staczek J; Harty RN; Garcia-Sastre A; Engelhardt OG; Palese P
Behring Inst Mitt; 1997 Feb; (98):291-301. PubMed ID: 9382753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
